Cost Effectiveness and Resource Allocation | |
Cost-utility analysis of genomic profiling in early breast cancer in Colombia | |
Research | |
Diego Rosselli1  Alejandro Ruiz-Patiño2  Juan Guillermo Ariza3  María X. Rojas-Reyes4  Andrés F. Cardona5  Leonardo Rojas6  | |
[1] Department of Clinical Epidemiology and Biostatistics, Faculty of Medicine, Pontificia Universidad Javeriana, Bogotá, Colombia;Foundation for Clinical and Applied Cancer Research-FICMAC, Bogotá, Colombia;Head Medical Affairs, Baxter International, Bogotá, Colombia;Institut d´Investigació Biomédica Sant Pau (IIB SANT PAU), Barcelona, Spain;Molecular Oncology and Biology Systems Research Group (Fox-G), Universidad El Bosque, Bogotá, Colombia;Foundation for Clinical and Applied Cancer Research-FICMAC, Bogotá, Colombia;Direction of Research, Science and Education, Fundación Centro de Tratamiento en Investigación Sobre Cáncer Luis Carlos Sarmiento Angulo (CTIC), Bogotá, Colombia;Thoracic and GU Unit, Fundación Centro de Tratamiento en Investigación Sobre Cáncer Luis Carlos Sarmiento Angulo (CTIC), Carrera 14 # 169 -49, Office 204, Bogotá, Colombia;Molecular Oncology and Biology Systems Research Group (Fox-G), Universidad El Bosque, Bogotá, Colombia; | |
关键词: Breast cancer; Personalized medicine; Cost-utility; | |
DOI : 10.1186/s12962-023-00449-5 | |
received in 2022-11-08, accepted in 2023-06-14, 发布年份 2023 | |
来源: Springer | |
![]() |
【 摘 要 】
BackgroundIn Colombia, the best strategy to establish indication for adjuvant chemotherapy in early breast cancer (EBC) remains unknown. This study aimed to identify the cost-utility of Oncotype DX™ (ODX) or Mammaprint™ (MMP) tests to establish the necessity of adjuvant chemotherapy.MethodsThis study used an adapted decision-analytic model to compare cost and outcomes of care between ODX or MMP tests and routine care without ODX or MMP tests (adjuvant chemotherapy for all patients) over a 5-year time horizon from the perspective of the Colombian National Health System (NHS; payer). Inputs were obtained from national unit cost tariffs, published literature, and clinical trial database. The study population comprised women with hormone-receptor-positive (HR +), HER2-negative, lymph-node-negative (LN0) EBC with high-risk clinical criteria for recurrence. The outcome measures were discounted incremental cost-utility ratio (ICUR; 2021 United States dollar per quality-adjusted life-year [QALY] gained) and net monetary benefit (NMB). Probabilistic (PSA) and deterministic sensitivity analysis (DSA) were performed.ResultsODX increases QALYs by 0.05 and MMP by 0.03 with savings of $2374 and $554 compared with the standard strategy, respectively, and were cost-saving in cost-utility plane. NMB for ODX was $2203 and for MMP was $416. Both tests dominate the standard strategy. Sensitivity analysis revealed that with a threshold of 1 gross domestic product per capita, ODX will be cost-effective in 95.5% of the cases compared with 70.2% cases involving MMP.DSA showed that the variable with significant influence was the monthly cost of adjuvant chemotherapy. PSA revealed that ODX was a consistently superior strategy.ConclusionsGenomic profiling using ODX or MMP tests to define the need of adjuvant chemotherapy treatment in patients with HR + and HER2 −EBC is a cost-effective strategy that allows Colombian NHS to maintain budget.
【 授权许可】
CC BY
© The Author(s) 2023
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202309143389633ZK.pdf | 1148KB | ![]() |
|
Fig. 4 | 1520KB | Image | ![]() |
Fig. 2 | 280KB | Image | ![]() |
MediaObjects/13690_2023_1133_MOESM5_ESM.docx | 14KB | Other | ![]() |
Fig. 4 | 3452KB | Image | ![]() |
【 图 表 】
Fig. 4
Fig. 2
Fig. 4
【 参考文献 】
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
- [7]
- [8]
- [9]
- [10]
- [11]
- [12]
- [13]
- [14]
- [15]
- [16]
- [17]
- [18]
- [19]
- [20]
- [21]
- [22]
- [23]
- [24]
- [25]
- [26]
- [27]
- [28]
- [29]
- [30]
- [31]
- [32]
- [33]
- [34]
- [35]
- [36]
- [37]
- [38]
- [39]
- [40]
- [41]
- [42]
- [43]
- [44]
- [45]
- [46]
- [47]
- [48]
- [49]
- [50]
- [51]